Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
AssigneeJunctucell Biomed Manufacturing GmbH
InventorsChristine Günther, Stefanos Theoharis, Felix Hermann, Ralf Huss
Life of this patent
Estimating the term…
Abstract
A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.
Claims21
A method of treating a tumor in a subject comprising administering a genetically modified mesenchymal stem cell (MSC), wherein said MSC comprises one or more exogenous nucleic acid molecule(s), wherein said one or more exogenous nucleic acid molecule(s) comprises one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines comprise at least IL-7, and at least one of IL-12 or IL-21.
Dependencies are inferred from the claim text.